681433-92-1

Basic information

• Product Name: 3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[(tert-butyldimethylsilyl)oxyethylidene]cyclohexanol
• Synonyms: 3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[(tert-butyldimethylsilyl)oxyethylidene]cyclohexanol
• CAS NO: 681433-92-1
• Molecular Weight: 514.969
• Mol File: 681433-92-1.mol

Chemical Properties

• CAS DataBase Reference: 3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[(tert-butyldimethylsilyl)oxyethylidene]cyclohexanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[(tert-butyldimethylsilyl)oxyethylidene]cyclohexanol(681433-92-1)
• EPA Substance Registry System: 3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[(tert-butyldimethylsilyl)oxyethylidene]cyclohexanol(681433-92-1)

Safety Data

• Hazardous Substances Data: 681433-92-1(Hazardous Substances Data)

Upstream product

• 681830-91-1 3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[(trimethylsilyl)oxy]cyclohexanol benzyl ether 
• 681830-92-2 2,6-bis-[(tert-butyldimethylsilyl)oxy]-4-(benzyloxy)cyclohexanol 
• 681433-62-5 (2R,6R)-2,6-bis-[(tert-butyldimethylsilyl)oxy]-4-(benzyloxy)cyclohexanone 
• 681830-90-0 3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[(trimethylsilyl)oxy]cyclohexanol 
• 141404-09-3 (3R,5R)-3,5-bis<(tert-butyldimethylsilyl)oxy>-4-<(trimethylsilyl)oxy>cyclohexanone 

Downstream Products

• 681433-94-3 (3R,5R)-[3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[2-(tert-butyldimethylsilyl)oxyethyl]cyclohexylidene]ethanol 
• 681433-95-4 (3R,5R)-[3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[2-(tert-butyldimethylsilyl)oxyethyl]cyclohexylidene]ethyldiphenylphoshine oxide 
• 681433-93-2 (3R,5R)-[3,5-bis-[(tert-butyldimethylsilyl)oxy]-4-[2-(tert-butyldimethylsilyl)oxyethyl]cyclohexylidene]acetic acid methyl ester 

Relevant articles and documents

Synthesis and biological activities of new 1α,25-dihydroxy-19-norvitamin D3 analogs with modifications in both the A-ring and the side chain

In a series of studies on structure-activity relationships of 2-substituted 19-norvitamin D analogs, we found that 1α,25-dihydroxy-19-norvitamin D3 analogs with 2β-hydroxyethoxy or 2E-hydroxyethylidene moieties show strong binding affinity for the vitamin D receptor (VDR) as well as marked transcriptional activity. To further examine the effects of side chain structure on the activity of 2-substituted 19-norvitamin D analogs, we have synthesized new 19-norvitamin D3 analogs with modifications in both the A-ring at the C(2) position and the side chain. The side chains of these analogs contained a double bond between C(22) and C(23) or an oxygen atom at C(22). The biological activity of the analogs was evaluated in vitro. All the side chain-modified analogs were less active than 1α,25-dihydroxyvitamin D3 1e and the parent compounds 3-6e possessing a natural 20R-configuration in binding to the VDR, but, except for the (20R)-22-oxa analogs 3-6d, were significantly more potent in transcriptional activity. Of the side-chain-modified analogs 4 and 5, the 2β-hydroxyethoxy- and 2E-hydroxyethylidene-22,24-diene-24a,26a,27a-trihomo analogs showed markedly higher transcriptional activity (25- and 17.5-fold, respectively) compared with 1e. Elongation of the side chain at the C-24, C-26, and C-27 positions and introduction of a 22,24-diene moiety strongly increased transcriptional activity, as seen in the 20-epi analogs 3-6f.

2,2-DI-SUBSTITUTED 1a,25-DIHYDROXY-19-NORVITAMIN D DERIVATIVE

An object of the present invention is to provide a novel 2,2-disubstituted-19-norvitamin D derivative. According to the present invention, there is provided a compound represented by the general formula (I): (wherein, R1 and R2 may be the same or differen